Atherosclerosis is a chronic inflammatory disease involving a complex interplay between resident vascular wall cells and infiltrating immune cells. Loss of T cell homeostasis contributes to both plaque development and inflammation. Regulatory T cells (Tregs) inhibit atherosclerotic development and progression through suppression of immune responses, including the actions of pro-inflammatory T helper 17 (Th17) cells. We identified the expression of the nuclear receptors PPARy and REVERBa/B in thoracic periaortic Tregs and Th17 cells, respectively. Our underlying hypothesis is that the development of the atherogenic lesion is driven by a pro-inflammatory gene network that can be modulated at the transcriptional level by PPARy and REVERBa/B. Our approach is to employ complementary loss-of-function and drug? mediated gain-of-function mouse studies, as well as genome-wide transcriptomic and cistromic studies, to define the molecular mechanisms of PPARy and REVERBs actions in atherogenesis.
In Aim 1, we will employ a novel Treg-specific PPARy knockout mouse in combination with PPARy agonists, to understand the role of PPARy-dependent signaling in visceral adipose tissue-resident Tregs during the development of atherosclerosis.
In Aim 2 we will determine PPARy's genome-wide chromatin binding sites, define the PPARy-dependent transcriptome, and map the translatome (Ribo-seq) of peri-aortic fat Tregs in order to determine the signaling pathways and molecular mechanisms of PPARy action in Tregs.
In Aim 3 we will examine the role of REVERBa/B in attenuating pro-Inflammatory Th17 cells in the context of atherogenesis. These REVERBs naturally oppose RORy, the Th17 lineage specifier. Our approach is to utilize mice with selective deletion of both REVERBa and REVERBB in T cells, in combination with the biologically-available REVERB agonist, SR9009, to determine the consequences of REVERB signaling on the differentiation of Th17 cells and the resultant effects on the initiation and progression of atherosclerosis. Similarly, in Aim 4 we will identify direct and indirect target genes of REVERBa and REVERBB by comparing their genome? wide chromatin binding sites to the REVERB-dependent transcriptomes in Th17 cells, thereby shedding light on the mechanisms of REVERB-mediated repression. These highly integrated Aims employ biochemical, molecular, genetic, pharmacologic and physiologic approaches to clarify the competing roles of the immuno? suppressive Tregs and the pro-inflammatory Th17 cells in this disease. Characterization of the roles of these therapeutically-accessible nuclear receptors in these immune cell populations may lead to the development of novel small molecule drugs for the prevention and treatment of atherosclerosis.

Public Health Relevance

This proposal is directed at identifying how nuclear receptors regulate the adaptive immune response integral to the development and progression of atherosclerosis. Insights gained from this work into the receptor-regulated pathways may lead to the development of new diagnostics and therapeutics for cardiovascular disease, the leading cause of death in the Western world.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL088093-06A1
Application #
8703252
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
6
Fiscal Year
2014
Total Cost
$601,400
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Winkels, Holger; Ehinger, Erik; Ghosheh, Yanal et al. (2018) Atherosclerosis in the single-cell era. Curr Opin Lipidol 29:389-396
Prohaska, Thomas A; Que, Xuchu; Diehl, Cody J et al. (2018) Massively Parallel Sequencing of Peritoneal and Splenic B Cell Repertoires Highlights Unique Properties of B-1 Cell Antibodies. J Immunol 200:1702-1717
Kobiyama, Kouji; Vassallo, Melanie; Mitzi, Jessica et al. (2018) A clinically applicable adjuvant for an atherosclerosis vaccine in mice. Eur J Immunol 48:1580-1587
Liu, Chao; Kim, Young Sook; Kim, Jungsu et al. (2018) Modeling hypercholesterolemia and vascular lipid accumulation in LDL receptor mutant zebrafish. J Lipid Res 59:391-399
Hoeksema, Marten A; Glass, Christopher K (2018) Nature and nurture of tissue-specific macrophage phenotypes. Atherosclerosis :
Winkels, Holger; Ehinger, Erik; Vassallo, Melanie et al. (2018) Atlas of the Immune Cell Repertoire in Mouse Atherosclerosis Defined by Single-Cell RNA-Sequencing and Mass Cytometry. Circ Res 122:1675-1688
Schneider, Dina A; Choi, Soo-Ho; Agatisa-Boyle, Colin et al. (2018) AIBP protects against metabolic abnormalities and atherosclerosis. J Lipid Res 59:854-863
Hartmann, Phillipp; Hochrath, Katrin; Horvath, Angela et al. (2018) Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology 67:2150-2166
Ahmadian, Maryam; Liu, Sihao; Reilly, Shannon M et al. (2018) ERR? Preserves Brown Fat Innate Thermogenic Activity. Cell Rep 22:2849-2859
Kobiyama, Kouji; Ley, Klaus (2018) Atherosclerosis. Circ Res 123:1118-1120

Showing the most recent 10 out of 172 publications